Table 5.

Relationship between ALB and chronic kidney disease progression in different models with the competing risk of mortality

Exposure	Crude model (SHR,95%CI, P )		Model I (SHR,95%CI, P )		Model II (SHR,95%CI, P )
ALB	0.34 (0.29, 0.41)	< 0.001	0.44 (0.36, 0.54)	< 0.001	0.60 (0.45, 0.81)	< 0.001
ALB Quartile
Q1	Ref		Ref		Ref
Q2	0.34 (0.25, 0.48)	< 0.001	0.44 (0.31, 0.62)	< 0.001	0.69 (0.47, 1.01)	0.06
Q3	0.19 (0.13, 0.29)	< 0.001	0.27 (0.18, 0.41)	< 0.001	0.45 (0.29, 0.70)	< 0.001
Q4	0.10 (0.06, 0.15)	< 0.001	0.15 (0.09, 0.25)	< 0.001	0.42(0.25, 0.72)	< 0.05
P for trend	< 0.001		< 0.001		< 0.001

Crude model: we did not adjust other covariants

Model I: we adjust age, BMI, gender, hypertension, SBP, history of CVD, diabetes, and etiology of CKD

Model II: we adjust age, BMI, gender, SBP, diabetes, hypertension, etiology of CKD, use of calcium channel blocker, UPCR, history of CVD, eGFR, urinary occult blood, Hb, use of RAAS inhibitor, use of diuretics

CI Confidence, Ref Reference, SHR Subdistribution hazard ratios